Kazakhstan's medicines evaluation centre. With the Ministry of Health's Committee for Medical and Pharmaceutical Control it evaluates and authorises medicines, and in April 2026 WHO rated Kazakhstan's regulatory system at maturity level 3.
The National Center for Expertise of Medicines and Medical Devices is a state enterprise of the Ministry of Health; its website gives its address as 13 Amangeldy Imanov Street, Astana (the coordinates are an approximate city point). WHO describes Kazakhstan's regulatory system as led by the Ministry of Health and implemented through the Committee for Medical and Pharmaceutical Control and this centre, which together oversee medicines and vaccines from evaluation and authorisation to market surveillance and safety monitoring.
On 9 April 2026 WHO announced that Kazakhstan had reached maturity level 3 under its Global Benchmarking Tool for the regulation of medicines and imported vaccines, the first country in Central Asia to do so. Kazakhstan registers medicines under the common rules of the Eurasian Economic Union; Forbes Kazakhstan reported in June 2021 that national registration would end on 1 July 2021 and that registrations issued under national law would lapse at the end of the transition on 1 January 2026. Under article 196 of the Code on public health, medicines used in free care must be registered in Kazakhstan and included in the Kazakhstan National Drug Formulary, with exceptions for a named patient's vital need.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/